#1970 Mortality prediction of plasma presepsin in sepsis-associated acute kidney injury patients requiring continuous kidney replacement therapy

Abstract

Abstract Background and Aims Presepsin has recently introduced as a more specific biomarker for sepsis. Presepsin is greatly affected by kidney function, so its reliability may be reduced in acute kidney injury (AKI) patient, especially requiring continuous kidney replacement therapy (CKRT). For this reason, there has been no study to date analyzing presepsin in AKI patients requiring CKRT. This study analyzed the usefulness of plasma presepsin for predicting mortality in AKI patients requiring CKRT, especially in sepsis-associated AKI (SA-AKI). Method This single-center, retrospective study included the patients who underwent CKRT with plasma presepsin measurement from April 2022 to March 2023. A total of 57 patients were enrolled, of which 35 were SA-AKI. 28-day mortality predictive values of plasma presepsin, Acute Physiology and Chronic Health Evaluation-II (APACHE-II), and Sequential Organ Failure Assessment (SOFA) scores were analyzed using receiver operating characteristics (ROC) curve analysis. Multivariate Cox regression analysis was performed to identifying risk factors for 28-day mortality in the SA-AKI subgroup. Results In the overall cohort, plasma presepsin showed the lower area under the ROC (AuROC) value of 0.636 than those of APACHE-II (0.663) and SOFA (0.731) scores. However, in SA-AKI subgroup, AuROC value of plasma presepsin was much increased to 0.799, which was the higher than those of APACHE-II (0.651) and SOFA (0.697) scores. Moreover, in multivariate Cox regression analysis, high presepsin was observed as an independent risk factor for 28-day mortality in the SA-AKI subgroup (HR 6.868, P=0.005). Conclusion Presepsin can be used as a good prognostic marker in SA-AKI patients requiring CKRT. The usefulness of plasma presepsin in the patients undergoing CKRT needs to be further studied in the future.